PHCY 514 Exam 2 Questions With
Verified Answers
Which is NOT a use of recombinant DNA technology:
A. Creation of human protein therapies
B. Creation of unique therapeutic fusion proteins
C. Creation of unique diagnostic fusion proteins
D. Creation of small molecules to produce therapies - ANSWER d
TRAIL is a potent anticancer protein. Creation of a TRAIL-based protein therapy
begins with isolating the _____________?
A. DNA cloning and assembly
B. Cell culture
C. Protein isolation
D. Cancer cells sensitive to TRAIL - ANSWER a
_______________ are small "protein factories" that produce therapeutic proteins
before they are isolated and lyopholized.
A. Transfection reagents
B. DNA plasmids
C. Chemical reactions
D. Cells - ANSWER d
Which of the following is correct:
A. A biosimilar has identical clinical properties to the original biologic.
B. Biologics are complex molecules produced using biological systems.
C. Biologics can include chemically synthesized small molecules
D. A biosimilar has identical physicochemical properties to the original biologic.
- ANSWER b
Which is NOT an example of biologics?
A. Cytokine
B. Monoclonal antibodies
C. Adeno-associated viral gene vectors
D. Aspirin - ANSWER d
Protein drugs are comprised of:
A. Chains of amino acids
B. Chemically linked small molecule compounds
C. DNA and RNA
, D. Cells of the immune system - ANSWER a
Which statement is true regarding small molecule drugs and protein drugs?
A. Protein therapies have more established guidelines for manufacturing and
testing than small molecule drugs
B. Protein therapies are more stable than small molecule drugs
C. Small molecule drugs exist for every therapeutic target
D. A protein therapy can be generated for every defective gene since the
human genome has been sequenced - ANSWER d
Inclusion of antioxidants:
A. Reduces formation of disulfide bridges
B. Likely has no impact on disulfide bridge formation
C. Increases formation of disulfide bridges - ANSWER a
Which is NOT a consequence of reduced stability of protein therapies?
A. Altered biodistribution
B. Decreased therapeutic efficacy
C. Altered function
D. Increased therapeutic efficacy - ANSWER d
________________ are natural weak spots in proteins where fragmentation
commonly occurs.
A. Hinge regions
B. Binding pockets
C. C-terminus
D. N-terminus - ANSWER a
Lyophilization improves protein stability by removing _____________ that is/are
the primary culprit of protein destabilization.
A. Water
B. DNA
C. Antioxidants
D. Polymers - ANSWER a
Cell- and virus-based delivery systems improve protein therapies by:
A. Reducing protein aggregation
B. Reducing protein fragmentation
C. Improving stabilization
D. Providing sustained production of therapeutic proteins in the body - ANSWER
d
The ideal concentration for liquid protein formulations to prevent absorption is a
"medium" concentration of:
A. 1-10 mg/ml
B. 20-50 mg/ml
Verified Answers
Which is NOT a use of recombinant DNA technology:
A. Creation of human protein therapies
B. Creation of unique therapeutic fusion proteins
C. Creation of unique diagnostic fusion proteins
D. Creation of small molecules to produce therapies - ANSWER d
TRAIL is a potent anticancer protein. Creation of a TRAIL-based protein therapy
begins with isolating the _____________?
A. DNA cloning and assembly
B. Cell culture
C. Protein isolation
D. Cancer cells sensitive to TRAIL - ANSWER a
_______________ are small "protein factories" that produce therapeutic proteins
before they are isolated and lyopholized.
A. Transfection reagents
B. DNA plasmids
C. Chemical reactions
D. Cells - ANSWER d
Which of the following is correct:
A. A biosimilar has identical clinical properties to the original biologic.
B. Biologics are complex molecules produced using biological systems.
C. Biologics can include chemically synthesized small molecules
D. A biosimilar has identical physicochemical properties to the original biologic.
- ANSWER b
Which is NOT an example of biologics?
A. Cytokine
B. Monoclonal antibodies
C. Adeno-associated viral gene vectors
D. Aspirin - ANSWER d
Protein drugs are comprised of:
A. Chains of amino acids
B. Chemically linked small molecule compounds
C. DNA and RNA
, D. Cells of the immune system - ANSWER a
Which statement is true regarding small molecule drugs and protein drugs?
A. Protein therapies have more established guidelines for manufacturing and
testing than small molecule drugs
B. Protein therapies are more stable than small molecule drugs
C. Small molecule drugs exist for every therapeutic target
D. A protein therapy can be generated for every defective gene since the
human genome has been sequenced - ANSWER d
Inclusion of antioxidants:
A. Reduces formation of disulfide bridges
B. Likely has no impact on disulfide bridge formation
C. Increases formation of disulfide bridges - ANSWER a
Which is NOT a consequence of reduced stability of protein therapies?
A. Altered biodistribution
B. Decreased therapeutic efficacy
C. Altered function
D. Increased therapeutic efficacy - ANSWER d
________________ are natural weak spots in proteins where fragmentation
commonly occurs.
A. Hinge regions
B. Binding pockets
C. C-terminus
D. N-terminus - ANSWER a
Lyophilization improves protein stability by removing _____________ that is/are
the primary culprit of protein destabilization.
A. Water
B. DNA
C. Antioxidants
D. Polymers - ANSWER a
Cell- and virus-based delivery systems improve protein therapies by:
A. Reducing protein aggregation
B. Reducing protein fragmentation
C. Improving stabilization
D. Providing sustained production of therapeutic proteins in the body - ANSWER
d
The ideal concentration for liquid protein formulations to prevent absorption is a
"medium" concentration of:
A. 1-10 mg/ml
B. 20-50 mg/ml
